跳至主要内容
临床试验/DRKS00032977
DRKS00032977招募中不适用

Molecular Tumor Board - A Registry of the East German Hematology and Oncology Study Group. - MTBreg-OSHO

Martin-Luther-Universität Halle-Wittenberg0 个研究点目标入组 250 人开始时间: 2023年11月2日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
250

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
one 至 one(—)
性别
All

入选标准

  • Signed consent form
  • - Hematological or oncological disease
  • - Present question regarding molecular diagnostics or therapy

排除标准

  • No questioning in the context of the molecular tumor board

研究者

相似试验

招募中
不适用
Register study of the Molecular Tumor Board (tumor entity-spanning molecular characterization program to evaluate individualized tumor biology-guided therapy in adults with rare and advanced tumor entities)Cross-tumor entity (adult patients = 18 years of age with any advanced tumor disease or with rare tumor entity (incidence of less than one case per 100,000 population)).N/A
DRKS00025847niversitätsklinikum Freiburg Klinik für Innere Medizin I Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation1,000
招募中
不适用
Registry of the molekularen tumor boards of the University Cancer Centers Schleswig-Holstein (short title: „UCCSH-MTB-registry)solid tumors and hematologic neoplasiaC00-C97Malignant neoplasms
DRKS00028806niversitätsklinikum Schleswig-Holstein, Lübeck Klinik für Hämatologie und Onkologie1,000
招募中
不适用
Molecular Tumor Board at the Center for Personalized Medicine TübingenAdvanced Cancer
NCT03503149University Hospital Tuebingen1,000
招募中
不适用
The Cancer Molecular Screening and Therapeutics (MoST) Program-ScreeningCancer - Any cancerCancer
ACTRN12616000908437niversity of Sydney7,628
进行中(未招募)
1 期
Tumor profilingPatients with locally advanced and/ or metastasized carcinoma for whom no further evidence-based drug treatment is established.A progression of the tumor is confirmed due to the last evidence-based drug therapy. Due to circulating tumor-DNA (ctDNA) in a blood sample and/or tissue sample of metastasis, a molecular-biologic tumor profiling is performed and an adapted tumor-specific drug therapy is selected.
EUCTR2014-005341-44-ATMedical University of Graz64
Molecular Tumor Board - A Registry of the East... | 临床试验